Journal of Orthopedic Oncology
Open Access

Bone-targeted agents; Breast cancer; Bone biopsy

Introduction

Twelve patients were collected; one patient had no bone metastases, three had limited bone metastases (LSM) with fewer than three lesions, and seven had extensive bone metastases (ESM) with more than three lesions [1]. The majority of the primary tumors tested positive for the estrogen receptor (ER) or progesterone receptor (PR). The procedure went off without a hitch. In 11 of the 12 patients, the quality of the sample was sufficient to conduct histomorphometric studies of bone turnover and trabecular structure.

The morphometric analysis of tumor invasion and the imaging data were well correlated. There was no evidence of tumor invasion in patients with no or minimal bone metastases [2]. When treated with BTA, most had reduced bone turnover and no discernible bone formation. In contrast, the number of osteoclasts in 6 out of 7 patients who had extensive bone invasion detected by imaging and evidence of tumor cells in the marrow showed intense osteoclastic activity. Six of these seven ESM patients received BTA treatment, but five of them showed resistance to it due to the high number of osteoclasts present. 3 of these 6 patients had dynamic bone arrangement [3].

Result

Three out of six patients with ESM and all three with LSM responded to BTA based on osteoblast activity and bone formation. According to tetracycline labeling, all patients treated with BTA exhibited a tendency toward suppression of bone formation in comparison to untreated patients [4]. Although limited by the small sample size, there was also a trend toward a significant difference between ESM and LSM treated with BTA, strongly suggesting resistance. According to our findings, morphometric analysis of bone tissues and imaging assessments of tumor invasion and burden are highly correlated in a trans-iliac bone biopsy performed with a 2 mm trephine [5]. Option, our methodology gives extra robotic data on helpful reaction to BTA supporting the ongoing clinical comprehension that most of patients with broad bone association at last fall flat to smother bone turnover [6]. This recommends that antiresorptive treatments become less viable as illness advances.

Discussion

Despite the widespread use of highly potent BTAs in breast cancer patients, such as intravenous bisphosphonates and denosumab, little is known about their in vivo effects on bone homeostasis, microarchitecture, and quality. The microarchitecture, turnover rate, degree of calcification, and properties of bone matrix collagens all play a significant role in bone strength. The accumulation of naturally occurring bone aging, therapies that have a negative impact on bone quality, and tumor cell invasion of bone complicate the assessment of bone strength in breast cancer patients. In this population at high risk for fractures, BTAs are frequently used to prevent osteoporosis and cancer treatment-induced bone loss , as well as in the adjuvant setting to reduce the risk of bone relapse ; Collective of Early Breast Cancer Trialists. Additionally, these agents are used to reduce pain, improve quality of life, and reduce skeletal related events (SREs) in patients with bone metastases. Paget proposed the “seed and soil” hypothesis more than one hundred years ago. In this theory, he hypothesized that tumor cells “seed,” or locate favorable terrain in the bone microenvironment (soil), where they can grow and multiply.

Conclusion

Additionally, it is hypothesized that antiresorptive drugs like bisphosphonates and denosumab make the “soil” less favorable to the development of skeletal metastases, which in turn reduces SREs. However, there has not yet been a direct evaluation of these agents’ effects on local bone turnover and invasion. A more prominent comprehension of what in fact happens in every patient could prompt more customized treatment and advancement of new specialists . Additionally, both momentary side impacts, like hypocalcemia and long haul poison levels like abnormal cracks, and osteonecrosis of the jaw , might actually be better gotten it. Bone turnover markers have been extensively studied in osteoporosis and patients with skeletal metastasis, but these technologies cannot assess bone morphology or changes caused by tumor bone invasion. Dual-energy X-ray absorptiometry (DEXA) and quantitative CT (QCT) are well-established non-invasive tests for assessing bone mass.

1. Chick JF, Chauhan NR, Madan R (2013) Solitary fibrous tumors of the thorax: nomenclature, epidemiology, radiologic and pathologic findings, differential diagnoses, and management. AJR Am J Roentgenol 200: 238-248.

Indexed at, Google Scholar, Crossref

2. Doyle LA (2014) Sarcoma classification: an update based on the 2013 World Health Organization classification of tumors of soft tissue and bone. Cancer 120: 1763-74.

Indexed at, Google Scholar, Crossref

3. Vallat-Decouvelaere AV, Dry SM, Fletcher CD (1998) Atypical and malignant solitary fibrous tumors in extrathoracic locations: evidence of their comparability to intra-thoracic tumors. Am J Surg Pathol 22:1501-1511?

Indexed at, Google Scholar, Crossref

4. Baldi GG, Stacchiotti S, Mauro V (2013) Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. Clin Sarcoma Res 3: 4.

Indexed at, Google Scholar, Crossref

5. Chiusaroli R, Piepoli T, Zanelli T, Ballanti P, Lanza M, et al. (2011) Rovati LC, Caselli G. Experimental pharmacology of glucosamine sulfate. Int J Rheumatol 2011: 939265.

Indexed at, Google Scholar, Crossref

6. Jones IA, Togashi R, Wilson ML, Heckmann N, Vangsness CT Jr, et al. (2019) Intra-articular treatment options for knee osteoarthritis. Nat Rev Rheumatol 15: 77-90.

Indexed at, Google Scholar, Crossref